TrialNature communications2024

Combination of acalabrutinib with lenalidomide and rituximab in relapsed/refractory aggressive B-cell non-Hodgkin lymphoma: a single-arm phase II trial.

Changhee Park et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.